5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;amino (2S)-5-amino-2-hydrazinyl-5-oxopentanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;amino (2S)-5-amino-2-hydrazinyl-5-oxopentanoate
• 化学式: C15H28N6O6S
• 分子量: 420.5
• InChiKey: ILRUVBGRZQPOHG-KYLREGBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  237
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• MODIFICATION AND COMPOSITIONS OF HUMAN SECRETOGLOBIN PROTEINS
  申请人：Therabron Therapeutics, Inc.

  公开号：EP3403666A1

  公开（公告）日：2018-11-21

  Novel compositions of recombinant human CC 10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCCIO have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCCIO which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

  通过对纯蛋白进行体外化学修饰，产生了重组人 CC 10 蛋白的新成分。通过利用活性氧和活性氮的过程，产生了几种含有经化学修饰的 rhCCIO 异构体的新合成制剂。这些制剂含有新型的 rhCCIO 异构体，与未修饰的蛋白质相比，它们的生物特性得到了增强或改变。含有新型异构体的制剂可用作标准物质，用于鉴定和表征血液或尿液中天然存在的原生 CC10 蛋白的异构体，并最终用于测量基于 CC10 的新生物标记物，以评估患者的疾病状况。这些制剂还可用于治疗呼吸系统、自身免疫系统、炎症和其他疾病，这些疾病使用未经修饰的蛋白质无法有效治疗。
• Modification and compositions of human secretoglobin proteins
  申请人：Therabron Therapeutics, Inc.

  公开号：US10294285B2

  公开（公告）日：2019-05-21

  Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.

  通过对纯蛋白进行体外化学修饰，产生了重组人 CC10 蛋白的新成分。通过利用活性氧和活性氮的过程，产生了几种新的合成制剂，其中含有经化学修饰的 rhCC10 异构体。这些制剂含有新型的 rhCC10 异构体，与未修饰的蛋白质相比，它们的生物特性得到了增强或改变。含有新型异构体的制剂可用作标准物质，用于鉴定和表征血液或尿液中天然存在的原生 CC10 蛋白的异构体，并最终测量基于 CC10 的新生物标记物，以评估患者的疾病状况。这些制剂还可用于治疗呼吸系统、自身免疫系统、炎症和其他疾病，这些疾病使用未经修饰的蛋白质无法有效治疗。
• MODIFICATION AND NOVEL COMPOSITIONS OF HUMAN SECRETOGLOBIN PROTEINS
  申请人：Therabron Therapeutics, Inc.

  公开号：EP2968449A2

  公开（公告）日：2016-01-20
• US20140275477A1
  申请人：——

  公开号：US20140275477A1

  公开（公告）日：2014-09-18
• Modification and Novel Compositions of Human Secretoglobin Proteins
  申请人：Therabron Therapeutics, Inc.

  公开号：US20160362462A1

  公开（公告）日：2016-12-15

  Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.